Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human 225Ac-PSMA-Trillium in advanced metastatic castration-resistant prostate cancer
NL-OMON59162Phase 1Recruiting
- Sponsor
- Bayer Consumer Health
- Start
- Dec 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAY 3563254 in prostate cancer (PCa), sponsored by Bayer Consumer Health. Started Dec 2025; status: recruiting.
02
Drugs
BAY 3563254
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59162.